Treatment of DVT and PE in the Emergency Medicine Setting
Why continue the endless routine of coagulation monitoring?
XARELTO® provides a proven safety profile with no required routine coagulation monitoring and eliminates the need for bridging.1-3
Proven efficacy and safety profile with convenient oral dosing
- A single, oral agent proven at least as effective as standard of care (enoxaparin + warfarin)
- 46% relative risk reduction (1.0% vs 1.7%) in major bleeding versus standard of care (enoxaparin + warfarin)*4
- Results confirmed in the largest DVT and PE phase 3 clinical trial program ever conducted (N=9477)
- Eliminates the need for bridging with a parenteral anticoagulant
DVT = deep vein thrombosis; PE = pulmonary embolism.